At the recent American Society of Hematology (ASH) annual meeting in San Diego, I had the opportunity to hear a few presentations on Acute Myeloid Leukemia (AML).
Those of you familiar with the ASH annual meeting will know that most of the oral presentations for the biology and therapies take place in simultaneous sessions on Monday. This sadly results in many session conflicts if you want to follow several products, pathways or multiple disease areas.
It’s unfortunate that there’s no virtual meeting such as at ASCO or that presentations are not more spread out during the meeting. My AML update is therefore focused specifically on FLT3 inhibition.